U.S. Markets close in 4 hrs 17 mins

NLS Pharmaceutics AG (NLSPW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.90010.0000 (0.00%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9001
Open1.1300
Bid0.7600 x 800
Ask0.7699 x 900
Day's Range0.9001 - 0.9001
52 Week Range0.4000 - 2.1800
Volume23
Avg. Volume2,028
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

    STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the initiation of its Phase 2 clinical trial evaluating Quilience® (mazindol extended release or "ER") as a once-daily monotherapy for the treatment of excessive daytime sleepine

  • ACCESSWIRE

    NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

    STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled topresent a corporate overview and participate in meetings with investors at the H.

  • ACCESSWIRE

    NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation

    STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a Notice of Allowance from the U.